# Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Canonical URL: https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f
Ticker: VKTX
Company: Viking Therapeutics
Source: Viking Therapeutics
Published: 2026-07-22 20:05 EST
Original Source URL: https://ir.vikingtherapeutics.com/2026-07-22-Viking-Therapeutics-to-Report-Financial-Results-for-Second-Quarter-2026-on-July-29,-2026
## Summary

Conference Call Scheduled for Wednesday, July 29, at 4:30 p.m. Eastern Time SAN DIEGO, July 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage...

## Article Body
Back to News & Events

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

Conference Call Scheduled for Wednesday, July 29, at 4:30 p.m. Eastern Time

, / PRNewswire / -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter of 2026 after the market close on Wednesday, July 29, 2026.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 29, 2026. To participate in the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until August 5, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference ID # 7609005. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts . An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biotechnology company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, and a Phase 1 study designed to evaluate maintenance dosing strategies to support long-term weight management. Viking's pipeline also includes additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com .

SOURCE Viking Therapeutics, Inc.

For further information: CONTACTS: Viking Therapeutics, Inc., Greg Zante, Chief Financial Officer, 858-704-4672, gzante@vikingtherapeutics.com. Vida Strategic Partners, Stephanie Diaz (Investors), 415-675-7401, sdiaz@vidasp.com. Jennifer Arcure (Media), 927-603-0681, jarcure@vidasp.com
## Recent Company News
- 2026-07-22 20:05 EST — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f) — Source: Viking Therapeutics
- 2026-06-24 11:05 EST — [Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1-study-to-evaluate-novel-amyl-743d8a79) — Source: Viking Therapeutics
- 2026-06-11 11:05 EST — [Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-appointment-of-hubert-c-chen-m-d-as-chief-medical--ca51f016) — Source: Viking Therapeutics
- 2026-05-21 11:05 EST — [Viking Therapeutics to Participate at Upcoming Investor Conferences](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-239640de) — Source: Viking Therapeutics
- 2026-05-12 11:05 EST — [Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026) — Source: Viking Therapeutics
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)